Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Men taking ACEI or ARB medications were more likely to have lower physical activity than the other two groups, whereas men taking an ARB medication had a greater weight than the other three groups.Descriptive statistics for men and women stratified by use of angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB)MenNon-users without hypertension (n = 239)Non-users with hypertension (n = 356)ACEI (n = 197)ARB (n = 107)p valueAge (yr)61.6 (54.3 to 72.5),range 50.2 to 96.671.2 (61.8 to 80.2),range 50.0 to 93.675.4 (66.3 to 82.2),range 50.5 to 92.773.4 (61.9 to 80.6),range 50.2 to 93.5 < 0.001Weight (kg)80.6 ± 13.181.8 ± 13.982.7 ± 14.185.3 ± 13.40.034Height (cm)174.1 ± 7.1172.3 ± 6.6171.8 ± 6.9172.3 ± 5.60.002Body mass index (kg/m2)26.5 ± 3.527.5 ± 4.228.0 ± 4.328.7 ± 4.2 < 0.001Systolic blood pressure (mmHg)126 (120 to 132)145 (135 to 157)138 (128 to 154)140 (130 to 154) < 0.001Diastolic blood pressure (mmHg)81 (76 to 85)91 (81 to 99)84 (75 to 92)84 (77 to 93) < 0.001High alcohol consumption49 (20.5)74 (20.8)38 (19.3)25 (23.4)0.897Falls (one or more over past 12 months)65 (27.2)113 (31.7)67 (34.0)31 (29.0)0.426Low physical activity60 (25.1)98 (27.5)70 (35.5)39 (36.5)0.033Smoking20 (8.4)40 (11.2)14 (7.1)9 (8.4)0.381Prior fracture40 (16.7)74 (20.8)28 (14.2)25 (23.4)0.123Statin use24 (10.0)74 (20.8)87 (44.2)35 (32.7) < 0.001Thiazide diuretic use0 (0.0)7 (2.0)16 (8.1)20 (18.7) < 0.001Antihypertension medication usea0 (0.0)127 (35.7)119 (60.4)58 (54.2) < 0.001Glucocorticoid use4 (1.7)12 (3.4)7 (3.6)3 (2.8): Medications with a positive effect on boneb7 (2.9)20 (5.6)12 (6.1)6 (5.6)0.746Charlson Comorbidity Score0 (0 to 1)0 (0 to 1)1 (0 to 2)0 (0 to 1) < 0.001SESc0.044 Quintile 1 (most disadvantaged)32 (13.4)75 (21.1)44 (22.3)22 (20.6) Quintile 247 (19.7)76 (21.4)51 (25.9)21 (19.6) Quintile 343 (18.0)82 (23.0)31 (15.7)20 (18.7) Quintile 457 (24.0)60 (16.9)30 (15.2)20 (18.7) Quintile 5 (most advantaged)60 (25.1)63 (17.7)41 (20.8)24 (22.4)Femoral neck BMD (g/cm2)0.954 ± 0.1280.947 ± 0.1500.929 ± 0.1480.944 ± 0.1530.380Any incident fracture31 (13.0)63 (17.7)38 (19.3)24 (22.4)0.487Incident fracture rate per 100,000 person years follow-up (95%CI)1.18 (0.80 to 1.67)1.80 (1.39 to 2.30)2.21 (1.57 to 3.01)2.51 (1.62 to 3.71) < 0.001WomenNon-users without hypertension (n = 220)Non-users with hypertension (n = 162)ACEI (n = 76)ARB (n = 116)p valueAge (yr)60.1 (55.2 to 67.2),range 50.1 to 92.269.8 (61.1 to 78.1),range 50.3 to 94.671.8 (63.0 to 79.2),range 50.7 to 92.268.8 (60.4 to 77.7),range 50.2 to 92.7 < 0.001Weight (kg)69.3 ± 13.373.3 ± 14.772.3 ± 17.076.6 ± 16.3 < 0.001Height (cm)161.4 ± 6.2159.0 ± 6.9158.2 ± 6.2159.1 ± 6.4 < 0.001Body mass index (kg/m2)26.6 ± 4.929.0 ± 5.628.8 ± 6.630.2 ± 6.1 < 0.001Systolic blood pressure (mmHg)123 (114 to 132)141 (130 to 151)136 (122 to 147)137 (127 to 146) < 0.001Diastolic blood pressure (mmHg)76 (71 to 80)82 (76 to 89)76 (69 to 85)78 (72 to 85) < 0.001High alcohol consumption14 (6.4)6 (3.7)2 (2.6)3 (2.6): Falls (one or more over past 12 months)60 (27.3)53 (32.7)29 (38.2)36 (31.0)0.361Low physical activity40 (18.2)58 (35.8)35 (46.1)47 (40.5) < 0.001Smoking27 (12.3)9 (5.6)6 (7.9)8 (6.9)0.099Prior fracture32 (14.5)37 (22.8)21 (27.6)24 (20.7)0.058Statin use23 (10.5)27 (16.7)23 (30.3)40 (34.5) < 0.001Thiazide diuretic use0 (0.0)7 (4.3)10 (13.2)22 (19.0) < 0.001Antihypertension medication usea0 (0.0)87 (53.7)52 (68.4)61 (52.6) < 0.001Glucocorticoid use6 (2.7)4 (2.5)2 (2.6)1 (0.9): Medications with a positive effect on boneb35 (15.9)15 (9.3)21 (27.6)18 (15.5)0.004Charlson Comorbidity Score0 (0 to 0)0 (0 to 1)1 (0 to 1)0 (0 to 1) < 0.001SESc0.272 Quintile 1 (most disadvantaged)29 (13.2)34 (21.0)14 (18.4)22 (19.0) Quintile 244 (20.0)30 (18.5)13 (17.1)19 (16.4) Quintile 348 (21.8)46 (28.4)20 (26.3)28 (24.1) Quintile 445 (20.5)22 (13.6)14 (18.4)29 (25.0) Quintile 5 (most advantaged)54 (24.6)30 (18.5)15 (19.7)18 (15.5)Femoral neck BMD (g/cm2)0.875 ± 0.1360.847 ± 0.1600.829 ± 0.1600.885 ± 0.1720.041Any incident fracture47 (21.4)36 (22.2)25 (32.9)27 (23.3)0.495Incident fracture rate per 100,000 person years follow-up (95%CI)2.26 (1.66 to 2.99)2.58 (1.81 to 3.55)4.05 (2.64 to 5.92)2.55 (1.69 to 3.69) < 0.001Data presented as mean ± SD, median(IQR) or n(%)aIncludes calcium channel blockers, beta blockers and diureticsbIncludes bisphosphonates, calcium and/or vitamin D supplements and hormone replacement therapycSocioeconomic statusMissing data: Men: weight n = 33, height n = 33, body mass index n = 33, blood pressure n = 91, alcohol consumption n = 49, falls n = 2, statin use n = 161, glucocorticoid use n = 161, medications with a positive effect on bone n = 161, femoral neck bone mineral density n = 65.
Source: Descriptive Characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Participants were drawn from the electoral roll, to which enrolment is compulsory in Australia, and age stratified to capture the full adult age-range.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Study design awaiting verification · Calcified Tissue International · 2022
Original publication title
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Medications used to treat hypertension may affect fracture risk. This study investigated fracture risk for users of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB). Participants (899 men, median age 70.3 yr (59.9 to 79.1), range 50.0 to 96.6 yr; 574 women, median age 65.5 yr (58.1 to 75.4), range 50.1 to 94.6 yr) were from the Geelong Osteoporosis Study. Medication use was self-reported and incident fractures were ascertained using radiological reports. Bone mineral density (BMD) was measured at the femoral neck. Participants were divided into four groups: (1) non-users without hypertension, (2) non-users with hypertension, (3) ACEI users and (4) ARB users.
Dosage was calculated using the defined daily dose (DDD) criteria. Participants were followed from date of visit to first fracture, death or 31 December 2016, whichever occurred first. Cox proportional hazards models were used for analyses. At least one incident fracture was sustained by 156 men and 135 women over a median(IQR) of 11.5(6.2 to 13.2) and 10.9(6.3 to 11.6) years of follow-up, respectively. In unadjusted analyses, compared to non-users without hypertension, men in all three other groups had a higher risk of fracture (Hazard Ratio (HR, 95%CI) 1.54, 1.00 to 2.37; 1.90, 1.18 to 3.05; 2.15, 1.26 to 3.66), for non-users with hypertension, ACEI and ARB users, respectively).
Following adjustment for age, prior fracture and BMD, these associations became non-significant. A dose effect for ARB use was observed; men using lower doses had a higher risk of fracture than non-users without hypertension, in both unadjusted (2.66, 1.34 to 5.29) and adjusted (2.03, 1.01 to 4.08) analyses, but this association was not observed at higher doses. For women, unadjusted analyses showed a higher risk for ACEI users compared to non-users without hypertension (1.74, 1.07 to 2.83). This was explained after adjustment for age, alcohol consumption, prior fracture and BMD (1.28, 0.74 to 2.22).
No other differences were observed. In men, lower dose (0 < DDD ≤ 1) ARB use was associated with an increased risk of fracture. ACEI or ARB use was not associated with increased risk of incident fracture in women. These findings may be important for antihypertensive treatment decisions in individuals with a high risk of fracture.
Authors’ abstract
Medications used to treat hypertension may affect fracture risk. This study investigated fracture risk for users of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB). Participants (899 men, median age 70.3 yr (59.9 to 79.1), range 50.0 to 96.6 yr; 574 women, median age 65.5 yr (58.1 to 75.4), range 50.1 to 94.6 yr) were from the Geelong Osteoporosis Study. Medication use was self-reported and incident fractures were ascertained using radiological reports. Bone mineral density (BMD) was measured at the femoral neck. Participants were divided into four groups: (1) non-users without hypertension, (2) non-users with hypertension, (3) ACEI users and (4) ARB users.
Dosage was calculated using the defined daily dose (DDD) criteria. Participants were followed from date of visit to first fracture, death or 31 December 2016, whichever occurred first. Cox proportional hazards models were used for analyses. At least one incident fracture was sustained by 156 men and 135 women over a median(IQR) of 11.5(6.2 to 13.2) and 10.9(6.3 to 11.6) years of follow-up, respectively. In unadjusted analyses, compared to non-users without hypertension, men in all three other groups had a higher risk of fracture (Hazard Ratio (HR, 95%CI) 1.54, 1.00 to 2.37; 1.90, 1.18 to 3.05; 2.15, 1.26 to 3.66), for non-users with hypertension, ACEI and ARB users, respectively).
Following adjustment for age, prior fracture and BMD, these associations became non-significant. A dose effect for ARB use was observed; men using lower doses had a higher risk of fracture than non-users without hypertension, in both unadjusted (2.66, 1.34 to 5.29) and adjusted (2.03, 1.01 to 4.08) analyses, but this association was not observed at higher doses. For women, unadjusted analyses showed a higher risk for ACEI users compared to non-users without hypertension (1.74, 1.07 to 2.83). This was explained after adjustment for age, alcohol consumption, prior fracture and BMD (1.28, 0.74 to 2.22).
No other differences were observed. In men, lower dose (0 < DDD ≤ 1) ARB use was associated with an increased risk of fracture. ACEI or ARB use was not associated with increased risk of incident fracture in women. These findings may be important for antihypertensive treatment decisions in individuals with a high risk of fracture.
Publication and source details
Original title: Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Kara L. Holloway-Kew; Amelia G. Betson; Kara B. Anderson; Filip Sepetavc; James Gaston; Mark A. Kotowicz; Wan-Hui Liao; Maciej Henneberg; Julie A. Pasco
Calcified Tissue International · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100000925National Health and Medical Research Council251638299831628582Pasco Julie A. Deakin UniversityOpen Access funding enabled and organized by CAUL and its Member Institutions
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T08:35:26.499349+00:00
DOI: 10.1007/s00223-022-01004-9 · PMC9474347